Algeta radiopharmaceutical meets primary endpoint

Algeta ASA’s investigational radiopharmaceutical (radium-223 chloride) that is being developed by Bayer Schering Pharma AG, has met its primary endpoint in a Phase 3 trial of patients with prostate cancer and bone metastases.